All In Biotech

Drug Trial Radar · NCT00631462

A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis

A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered TG101348 in Patients With Primary, Post-polycythemia Vera, or Post-essential Thrombocythemia Myelofibrosis

Last checked: Nov 21, 2026Latest source record: Oct 26, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

59

Actual

Start

Jan 2008

Primary completion

Oct 2009

Study completion Oct 2009

Sponsor

Lead sponsor
TargeGenIndustry
Sponsor type
Industry
First posted
Mar 7, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of orally administered TG101348 in patients with myelofibrosis.

Conditions

  • Myelofibrosis

Interventions

  • TG101348Drug

    Orally administered, once a day, for 28 days, up to 6 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (i.e., adverse events; effects on laboratory parameters, vital signs, and ECGs; dose-limiting toxicities), tolerability, and MTDTime frame: 28 days

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • UCSD Moores Cancer Center

    San Diego, California

  • Stanford Comprehensive Cancer Center

    Stanford, California

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Mayo Clinic, Rochester

    Rochester, Minnesota

  • MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.